SIGNATURE TOOL · SIDE-BY-SIDE RESEARCH
Compare Peptides
Compare structured records, protocol sources, women-specific metadata and connected research without collapsing unlike evidence into one score.
VS
At a glance
| FIELD | Retatrutide | Semaglutide |
|---|---|---|
| Record type | Single peptide | Single peptide |
| Research context | Triple receptor agonist · investigational | GLP-1 receptor agonist |
| Routes indexed | Subcutaneous | Subcutaneous · Oral |
| Last reviewed | 2026-09-09 | 2026-09-13 |
Research goals
| FIELD | Retatrutide | Semaglutide |
|---|---|---|
| Goal tags | Weight Management · Appetite · Glucose / Insulin · Fat Loss · Body Composition | Weight Management · Appetite · Glucose / Insulin · Fat Loss · Body Composition |
| Research areas | Weight Management · Glucose / Insulin | Weight Management · Appetite · Glucose / Insulin · Fat Loss |
Protocol structure
| FIELD | Retatrutide | Semaglutide |
|---|---|---|
| Variations indexed | 6 | 1 |
| Primary frequency | Once weekly | See indexed source |
| Duration | 48 weeks | 0 weeks |
| Stage detail | COMPLETE | PENDING SOURCE EXTRACTION |
Study / reference context
| FIELD | Retatrutide | Semaglutide |
|---|---|---|
| Protocol source | PUBLISHED STUDY · Jastreboff et al., NEJM 2023 | PUBLISHED STUDY · New England Journal of Medicine, 2021 |
| Indexed references | 6 | 1 |
| Reference types | CLINICAL TRIAL · SPONSOR UPDATE · REGULATORY | CLINICAL TRIAL |
Women in the research
| FIELD | Retatrutide | Semaglutide |
|---|---|---|
| Female participants | 163 | Not indexed |
| Women represented | 48.2% | Not indexed |
| Sex-specific outcomes | Reported | Not indexed |
Related goals
References
RetatrutideTriple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialCLINICAL TRIAL · 2023Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetesCLINICAL TRIAL · 2023Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver diseaseCLINICAL TRIAL · 2024TRIUMPH-1 Phase 3 topline resultsSPONSOR UPDATE · 2026TRIUMPH-2 and TRIUMPH-3 Phase 3 topline results and planned regulatory submissionSPONSOR UPDATE · 2026